Acute asthma exacerbation (peds): Difference between revisions
(23 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{Peds top}} [[asthma]] | |||
==Background== | ==Background== | ||
*An estimated 6 million children in the US have asthma | *An estimated 6 million children in the US have asthma | ||
Line 6: | Line 6: | ||
*A history of eczema or allergies maybe helpful in making a new diagnosis of asthma | *A history of eczema or allergies maybe helpful in making a new diagnosis of asthma | ||
*Wheezing in an infant is more often [[bronchiolitis]] than asthma | *Wheezing in an infant is more often [[bronchiolitis]] than asthma | ||
*Viral [[URI]], allergen exposure, and respiratory irritants (i.e. smoke) are common precipitants for pediatric asthma exacerbations | *Viral [[URI]] associated with copious rhinorrhea, allergen exposure, and respiratory irritants (i.e. smoke) are common precipitants for pediatric asthma exacerbations | ||
==Clinical Features== | ==Clinical Features== | ||
*Wheezing | *[[Wheezing]] | ||
*[[Cough]] | *[[Cough]] | ||
*Accessory muscle use | *Accessory muscle use | ||
*[[Dyspnea]] | *[[Dyspnea]] | ||
*Prolonged expiration | *Prolonged expiration | ||
*Severity of retractions occurs in caudal to cephalad direction | |||
**Scalene muscle contractions more severe than subcostal and intercostal retractions | |||
*Sign of impending ventilatory failure | *Sign of impending ventilatory failure | ||
**Paradoxical respiration | **Paradoxical respiration | ||
Line 24: | Line 26: | ||
==Evaluation== | ==Evaluation== | ||
[[File:CXR3354 IM-1609-1001.png|thumb|[[CXR]] with hyperinflated lungs consistent with broncoconstriction.]] | |||
*Clinical diagnosis | *Clinical diagnosis | ||
*Can consider a blood gas if there are fears that the patient is getting tired (sleepy baby vs [[hypercapnia|elevated CO2]]?) | |||
**A CO2 >45 is abnormal in a patient hyperventilating and warrants close monitoring | |||
===Consider [[CXR]]=== | ===Consider [[CXR]]=== | ||
Line 31: | Line 36: | ||
*Poor response to medications/treatment, if history and exam are not consistent with [[bronchiolitis]] | *Poor response to medications/treatment, if history and exam are not consistent with [[bronchiolitis]] | ||
*Worsening symptoms | *Worsening symptoms | ||
*Fever not explained by apparent viral illness | |||
===Clinical Scores=== | ===Clinical Scores=== | ||
Line 45: | Line 51: | ||
''Favor continuous nebulization to decrease the chance of admission when compared to intermittent dosing''<ref>Camargo CA et al. Continuous versus intermittent beta- agonists for acute asthma. Cochrane Database Syst Rev. 2003;(4):CD001115. PMID: 14583926.</ref> | ''Favor continuous nebulization to decrease the chance of admission when compared to intermittent dosing''<ref>Camargo CA et al. Continuous versus intermittent beta- agonists for acute asthma. Cochrane Database Syst Rev. 2003;(4):CD001115. PMID: 14583926.</ref> | ||
*Nebulizer | *Nebulizer | ||
** | **Intermittent: 2.5-5mg q20min, three doses are traditionally given back to back, then repeat as needed. | ||
**Continuous: 0.5mg/kg/hr (max 15mg/hr)<ref>National Asthma Education and Prevention Program (NAEPP), “Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,” Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</ref> | **Continuous: 0.5mg/kg/hr (max 15mg/hr)<ref>National Asthma Education and Prevention Program (NAEPP), “Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,” Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</ref> | ||
*MDI | *MDI | ||
Line 51: | Line 57: | ||
===[[Ipratropium]]=== | ===[[Ipratropium]]=== | ||
*0.5mg q20min, given with the first three doses of albuterol, it is shown to reduce admission. | *0.25-0.5mg q20min, given with the first three doses of albuterol, it is shown to reduce admission. | ||
===[[Steroids]]=== | ===[[Steroids]]=== | ||
''Should be given in the first hour with effects to reduce admission<ref name="Rowe">Rowe BH et al. Magnesium sulfate for treating exac- erbations of acute asthma in the emergency depart- ment. Cochrane Database Syst Rev. 2000;(2):CD001490. PMID: 10796650.</ref>'' | ''Should be given in the first hour with effects to reduce admission<ref name="Rowe">Rowe BH et al. Magnesium sulfate for treating exac- erbations of acute asthma in the emergency depart- ment. Cochrane Database Syst Rev. 2000;(2):CD001490. PMID: 10796650.</ref>'' | ||
*[[Dexamethasone]] | *[[Dexamethasone]] | ||
**0. | **0.6 mg/kg PO or IV (max 16 mg); consider 2nd dose 24-36hrs later.<ref>Cross KP, et al. Single-dose dexamethasone for mild-to-moderate asthma exacerbations. Can Fam Physician. 2011 Oct; 57(10): 1134–1136.</ref><ref>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. Pediatrics. 2020;145(1):e20193450. [PubMed 31871244]</ref><ref>Dexamethasone versus prednisone for children receiving asthma treatment in the paediatric inpatient population: protocol for a feasibility randomised controlled trial. BMJ Open. http://dx.doi.org/10.1136/bmjopen-2018-025630</ref> | ||
***PO and IV have equal efficacy. Giving the IV form by mouth is typically better tolerated by young children (same dosing) | ***PO and IV have equal efficacy. Giving the IV form by mouth is typically better tolerated by young children (same dosing) | ||
**Both 1 and 2 dose regimens as effective as [[prednisone]] or [[prednisolone]] in children <ref>Keeney, et al. Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis. Pediatrics. 2013-2273</ref><ref>Cronin et al. "A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department." Annals of EM. May 2016. 67(5):593-601</ref> | **Both 1 and 2 dose regimens as effective as [[prednisone]] or [[prednisolone]] in children <ref>Keeney, et al. Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis. Pediatrics. 2013-2273</ref><ref>Cronin et al. "A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department." Annals of EM. May 2016. 67(5):593-601</ref> | ||
Line 82: | Line 88: | ||
**Alleviates muscle fatigue which leads to larger tidal volumes | **Alleviates muscle fatigue which leads to larger tidal volumes | ||
**Maximize inspiratory support | **Maximize inspiratory support | ||
*** | ***Delta pressure 10 | ||
***PEEP | ***PEEP >4 | ||
**May benefit from [[ketamine]] or [[dexmedetomidine]] to mildly sedate and allow the interface | |||
* | |||
* | |||
===[[Intubation]]=== | ===[[Intubation]]=== | ||
*Consider induction with [[ | *Push pull (bolus) [[IVF|fluids]] prior to intubation to maximize the patient's preload and ideally decrease the chance of the patient arresting | ||
*Consider induction with [[ketamine]] | |||
**Provides bronchodilation and sedation however it does promote secretions | **Provides bronchodilation and sedation however it does promote secretions | ||
**Ketamine is the preferred induction agent for intubation in an asthmatic. | **Ketamine is the preferred induction agent for intubation in an asthmatic. | ||
**Dosing 1-2 mg/kg | **Dosing 1-2 mg/kg | ||
*Ventilation of asthmatic patients requires deep sedation | *Ventilation of asthmatic patients requires deep sedation | ||
**[[Benzos]], | **[[Benzos]], [[ketamine]] (1 mg/kg/hr) | ||
*[[Ventilation settings]] | *[[Ventilation settings]] | ||
**Assist-control ventilation | **Assist-control ventilation | ||
**Resp rate | **Resp rate | ||
***Start slow to avoid air-trapping and allow for longer expiration time | ***Start slow to avoid air-trapping and allow for longer expiration time | ||
Line 109: | Line 113: | ||
**Keep FiO2 minimum to achieve SpO2 > 90% | **Keep FiO2 minimum to achieve SpO2 > 90% | ||
*Use bronchodilators even when intubated | *Use bronchodilators even when intubated | ||
*Many patients require a continuous paralytic infusion for the first 24+ hrs of intubation | *Many patients require a continuous [[neuromuscular blocking agents|paralytic]] infusion for the first 24+ hrs of intubation | ||
==Outpatient Treatment== | ==Outpatient Treatment== | ||
Line 118: | Line 122: | ||
| align="center" style="background:*f0f0f0;"|'''Treatment (WHO 2008 Formulary)<ref>Stuart MC et al. WHO Model Formulary 2008. http://www.who.int/selection_medicines/list/WMF2008.pdf.</ref>''' | | align="center" style="background:*f0f0f0;"|'''Treatment (WHO 2008 Formulary)<ref>Stuart MC et al. WHO Model Formulary 2008. http://www.who.int/selection_medicines/list/WMF2008.pdf.</ref>''' | ||
|- | |- | ||
| Mild intermittent, > 80% peak flow||< 2/wk||< 2/mo||[[Albuterol]] MDI 100-200 mcg | | Mild intermittent, > 80% peak flow||< 2/wk||< 2/mo|| | ||
*[[Albuterol]] MDI 100-200 mcg PRN QID | |||
|- | |- | ||
| Mild persistent, > 80% peak flow||>2/wk||>2/mo||[[Albuterol]] MDI 100-200 mcg | | Mild persistent, > 80% peak flow||>2/wk||>2/mo|| | ||
*[[Albuterol]] MDI 100-200 mcg PRN QID '''AND''' | |||
[[Beclometasone]] 100-250 mcg | *[[Beclometasone]] 100-250 mcg BID | ||
|- | |- | ||
| Moderate persistent, 60-80% peak flow||Daily with exacerbations weekly||> 1/wk||[[Albuterol]] MDI 100-200 mcg | | Moderate persistent, 60-80% peak flow||Daily with exacerbations weekly||> 1/wk|| | ||
*[[Albuterol]] MDI 100-200 mcg PRN QID '''AND''' | |||
[[Beclometasone]] 100-500 mcg | *[[Beclometasone]] 100-500 mcg BID '''AND''' | ||
*[[Salmeterol]] inhaled 50 mcg BID | |||
[[Salmeterol]] inhaled 50 mcg | |||
|- | |- | ||
| Severe persistent, < 60% peak flow||Continuous daily||Frequent||[[Albuterol]] MDI 100-200 mcg | | Severe persistent, < 60% peak flow||Continuous daily||Frequent|| | ||
*[[Albuterol]] MDI 100-200 mcg PRN QID '''AND''' | |||
[[Beclometasone]] 1mg | *[[Beclometasone]] 1mg BID (high dose) '''AND''' | ||
*[[Salmeterol]] inhaled 50 mcg BID '''AND''' | |||
*[[Theophylline]], leukotriene antagonist, or PO [[prednisolone]] with taper | |||
[[Salmeterol]] inhaled 50 mcg | |||
|} | |} | ||
Line 157: | Line 156: | ||
==See Also== | ==See Also== | ||
*[[Modified pulmonary index score | *[[Asthma]] | ||
*[[Modified pulmonary index score]] | |||
*[[Ventilation settings]] | *[[Ventilation settings]] | ||
*[[Deterioration after intubation]] | *[[Deterioration after intubation]] | ||
*[[Shortness of breath]] | *[[Shortness of breath]] | ||
==External Links== | ==External Links== |
Revision as of 18:13, 1 February 2023
This page is for pediatric patients. For adult patients, see: asthma
Background
- An estimated 6 million children in the US have asthma
- In 2007, asthma lead to >700,000 ED visits
- Asthma is part of the atopy triad (asthma, allergies, eczema)
- A history of eczema or allergies maybe helpful in making a new diagnosis of asthma
- Wheezing in an infant is more often bronchiolitis than asthma
- Viral URI associated with copious rhinorrhea, allergen exposure, and respiratory irritants (i.e. smoke) are common precipitants for pediatric asthma exacerbations
Clinical Features
- Wheezing
- Cough
- Accessory muscle use
- Dyspnea
- Prolonged expiration
- Severity of retractions occurs in caudal to cephalad direction
- Scalene muscle contractions more severe than subcostal and intercostal retractions
- Sign of impending ventilatory failure
- Paradoxical respiration
- Chest deflation and abdominal protrusion during inspiration
- Altered mental status
- "Silent chest"
- Paradoxical respiration
Differential Diagnosis
Pediatric Wheezing
- Upper Airway diseases
- Large Airway Obstruction
- Foreign body aspiration
- Vascular ring or laryngeal webs
- Laryngotracheomalacia
- Enlarged lymph node or tumor
- Vocal cord dysfunction
- Small Airway Obstruction
- Asthma
- Viral bronchiolitis
- Cystic Fibrosis
- Bronchopulmonary dysplasia
- Congenital heart disease or other cardiac disease
- Other causes
Evaluation
- Clinical diagnosis
- Can consider a blood gas if there are fears that the patient is getting tired (sleepy baby vs elevated CO2?)
- A CO2 >45 is abnormal in a patient hyperventilating and warrants close monitoring
Consider CXR
- 1st wheezing episode
- Asymmetric lung auscultation findings, after treatment with albuterol
- Poor response to medications/treatment, if history and exam are not consistent with bronchiolitis
- Worsening symptoms
- Fever not explained by apparent viral illness
Clinical Scores
- Diagnosis and treatment can be guided by clinical scores
- Modified Pulmonary Index Score (MPIS - Utilized at CCMC)
- Pediatric Asthma Score (PAS)
- Pulmonary Score (PS)
- Pediatric Respiratory Assessment Measure (PRAM)
Modified Pulmonary Index Score (MPIS)
Age <3 Years | ||||||
---|---|---|---|---|---|---|
Points | SpO2 | Acces Musc Use | I:E | Wheeze | HR | RR |
0 | >95% | None | 2:1 | None; Good Aeration | ≤120 | ≤30 |
1 | 93-95% | Mild | 1:1 | End Exp | 121-140 | 31-45 |
2 | 90-92% | Moderate | 1:2 | Insp/Exp; Good Aeration | 141-160 | 46-60 |
3 | <90% | Severe | 1:3 | Insp/Exp; Poor Aeration | >160 | >60 |
Age 3-6 Years | ||||||
---|---|---|---|---|---|---|
Points | SpO2 | Acces Musc Use | I:E | Wheeze | HR | RR |
0 | >95% | None | 2:1 | None; Good Aeration | ≤100 | ≤30 |
1 | 93-95% | Mild | 1:1 | End Exp | 101-120 | 31-45 |
2 | 90-92% | Moderate | 1:2 | Insp/Exp; Good Aeration | 121-140 | 46-60 |
3 | <90% | Severe | 1:3 | Insp/Exp; Poor Aeration | >140 | >60 |
Age ≥6 Years | ||||||
---|---|---|---|---|---|---|
Points | SpO2 | Acces Musc Use | I:E | Wheeze | HR | RR |
0 | >95% | None | 2:1 | None; Good Aeration | ≤100 | ≤20 |
1 | 93-95% | Mild | 1:1 | End Exp | 101-120 | 21-35 |
2 | 90-92% | Moderate | 1:2 | Insp/Exp; Good Aeration | 121-140 | 36-50 |
3 | <90% | Severe | 1:3 | Insp/Exp; Poor Aeration | >140 | >50 |
- MPIS <7 - Mild exacerbation
- MPIS 7-10 - Moderate exacerbation
- MPIS ≥10 - Severe exacerbation
Management
Albuterol
Favor continuous nebulization to decrease the chance of admission when compared to intermittent dosing[1]
- Nebulizer
- Intermittent: 2.5-5mg q20min, three doses are traditionally given back to back, then repeat as needed.
- Continuous: 0.5mg/kg/hr (max 15mg/hr)[2]
- MDI
- 4-8 puffs q20min given in first hour, then q1-4hr as needed
Ipratropium
- 0.25-0.5mg q20min, given with the first three doses of albuterol, it is shown to reduce admission.
Steroids
Should be given in the first hour with effects to reduce admission[3]
- Dexamethasone
- 0.6 mg/kg PO or IV (max 16 mg); consider 2nd dose 24-36hrs later.[4][5][6]
- PO and IV have equal efficacy. Giving the IV form by mouth is typically better tolerated by young children (same dosing)
- Both 1 and 2 dose regimens as effective as prednisone or prednisolone in children [7][8]
- 0.6 mg/kg PO or IV (max 16 mg); consider 2nd dose 24-36hrs later.[4][5][6]
- Prednisone
- 1-2mg/kg/day (60mg max) in one or two divided doses for 3-5 days
- Methylprednisolone
- 1mg/kg IV q 4–6hr
- Only use IV if cannot tolerate PO since equal effectiveness between dosing routes[9]
Magnesium
- Dose: 50mg/kg IV, max 2-4 g over 20 mins with close blood pressure monitoring
- Smooth muscle relaxant
- Duration of action approximately 20 min
- In patients with moderate to severe asthma there is a decreased rate of admission with an NNT of 2[3]
Beta-agonist
- Epinephrine
- 1:1000 0.01mg/kg (max 0.3mg) IM, repeat as needed
- Terbutaline
- Given SQ, usual dose 0.01mg/kg up to 0.3mg.
- Longer-acting beta2-agonist promoting bronchodilation
Assisted Ventilation
- Non-invasive ventilation
- Consider as alternative to intubation
- Alleviates muscle fatigue which leads to larger tidal volumes
- Maximize inspiratory support
- Delta pressure 10
- PEEP >4
- May benefit from ketamine or dexmedetomidine to mildly sedate and allow the interface
Intubation
- Push pull (bolus) fluids prior to intubation to maximize the patient's preload and ideally decrease the chance of the patient arresting
- Consider induction with ketamine
- Provides bronchodilation and sedation however it does promote secretions
- Ketamine is the preferred induction agent for intubation in an asthmatic.
- Dosing 1-2 mg/kg
- Ventilation of asthmatic patients requires deep sedation
- Ventilation settings
- Assist-control ventilation
- Resp rate
- Start slow to avoid air-trapping and allow for longer expiration time
- Consider I:E ratio of 1:2 or 1:3
- Plateau pressure ideally <30
- May require "permissive hypoventilation" and permissive hypercarbia and acidosis
- Low peak pressure/avoidance of breath stacking more important than correcting CO2 [10]
- Tidal volume 6-8cc/kg ideal wt
- PEEP >4
- Flow rate 80-100L/min
- Keep FiO2 minimum to achieve SpO2 > 90%
- Use bronchodilators even when intubated
- Many patients require a continuous paralytic infusion for the first 24+ hrs of intubation
Outpatient Treatment
Severity | Day Sx | Night Sx | Treatment (WHO 2008 Formulary)[11] |
Mild intermittent, > 80% peak flow | < 2/wk | < 2/mo |
|
Mild persistent, > 80% peak flow | >2/wk | >2/mo |
|
Moderate persistent, 60-80% peak flow | Daily with exacerbations weekly | > 1/wk |
|
Severe persistent, < 60% peak flow | Continuous daily | Frequent |
|
Disposition
- Discharge
- Often, patients will still have mild wheezing, but should have complete resolution of tachypnea, hypoxia, and improved work of breathing
- A short course of glucocorticoids decreases chance of relapse [12])
- Patient should generally continue albuterol at home q6hrs for at least the first 24hrs after discharge
- A spacer should be prescribed to be used with the MDI to improve medication delivery to the lungs
- Admit
- If symptoms do not significantly improve or for severe exacerbations
- Peak flow measurements maybe helpful when deciding disposition
- Predicted = (30 x age (yrs)) + 30
- PEF >70% predicted → high likelihood of successful discharge
- PEF <40% predicted → should be admitted
See Also
- Asthma
- Modified pulmonary index score
- Ventilation settings
- Deterioration after intubation
- Shortness of breath
External Links
References
- ↑ Camargo CA et al. Continuous versus intermittent beta- agonists for acute asthma. Cochrane Database Syst Rev. 2003;(4):CD001115. PMID: 14583926.
- ↑ National Asthma Education and Prevention Program (NAEPP), “Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,” Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
- ↑ 3.0 3.1 Rowe BH et al. Magnesium sulfate for treating exac- erbations of acute asthma in the emergency depart- ment. Cochrane Database Syst Rev. 2000;(2):CD001490. PMID: 10796650.
- ↑ Cross KP, et al. Single-dose dexamethasone for mild-to-moderate asthma exacerbations. Can Fam Physician. 2011 Oct; 57(10): 1134–1136.
- ↑ Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. Pediatrics. 2020;145(1):e20193450. [PubMed 31871244]
- ↑ Dexamethasone versus prednisone for children receiving asthma treatment in the paediatric inpatient population: protocol for a feasibility randomised controlled trial. BMJ Open. http://dx.doi.org/10.1136/bmjopen-2018-025630
- ↑ Keeney, et al. Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis. Pediatrics. 2013-2273
- ↑ Cronin et al. "A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department." Annals of EM. May 2016. 67(5):593-601
- ↑ Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. Am J Emerg Med. Jul 1992;10(4):301-10
- ↑ Darioli, et al. Mechanical Controlled hypoventilation in status asthmaticus. Am Rev Respir Dis. 1984; 129 (3) 385-7
- ↑ Stuart MC et al. WHO Model Formulary 2008. http://www.who.int/selection_medicines/list/WMF2008.pdf.
- ↑ Chapman K. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. NEJM. 1991;324(12):788